MedTrace Logo

Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer

NCT06149767 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2023-11-29

No results posted yet for this study

Summary

Prospective single-arm clinical study of adebrelimab combined with concurrent chemoradiotherapy in locally advanced cervical cancer

Conditions

Interventions

DRUG

Adebrelimab

The medication regimen for all enrolled patients is as follows, and the dose can be adjusted during treatment due to adverse reactions and other circumstances: Adebrelimab : 20 mg/kg, D1, intravenously, 30-60 min, Q3w. Paclitaxel for Injection: 150 mg/m2, D1 Cisplatin: 50 mg/m2, IV, D1, Q3w. Radiotherapy: pelvic dose: 6MV-X, 180cGy/ times 27 times; Brachydose: 192Ir, 700cGy/ time 4 times. First of all, after 2 cycles of concurrent chemoradiotherapy, the sequential chemotherapy combined with adbalizumab for 2-4 cycles, and the subsequent investigators selected Adbalizumab or other drugs to maintain the treatment according to the patient's situation or the patient's own will until the disease progressed or intolerable toxicity occurred or the subjects voluntarily withdrew from the study.adebrelimab until disease progression or intolerable toxicity or the subject voluntarily withdrew from the study。

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2028-02-29
Completion
2028-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06149767 on ClinicalTrials.gov